SUBSCRIBE
SUBSCRIBE
News   Drug Development

Antigenics Inc. (New York) Buoyed by Brain-Cancer Study

October 26, 2009 | 
1 min read
Bookmark and Share

Drug developer Antigenics Inc. said researchers at the University of California, San Francisco, reported positive results stemming from a study using its cancer therapy Oncophage to treat brain-cancer patients.
Clinical research Phase 2
MORE ON THIS TOPIC
Businessman analyzing company's financial balance sheet working with digital augmented reality graphics. Businessman calculates financial data for long-term investment.
Autoimmune disease
Biogen’s big lupus bet gets boost from new durability data for skin disease
October 5, 2026
 · 
3 min read
 · 
Heather McKenzie
White directional arrow climbs geometric steps toward a red flag on blue halftone texture. Corporate progress, target achievement, leadership ambition and strategic growth concept.
Vaccines
Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
October 5, 2026
 · 
2 min read
 · 
Annalee Armstrong
Insights
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
October 5, 2026
 · 
6 min read
 · 
Jennifer C. Smith-Parker
Dude 3D characters X7 business people pushing up Red Graph. Light Blue 3D Grid background.
Duchenne muscular dystrophy
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
October 2, 2026
 · 
3 min read
 · 
Heather McKenzie